Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Cytomegalovirus Infections 4Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Multi-centric Castleman's Disease 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Solid Tumor, Adult 1Sezary Syndrome 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune Reconstitution Inflammatory Syndrome × Valganciclovir × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡